Shigeki Yagyu
Kyoto Prefectural University of Medicine
Messenger RNACell therapyHaematopoiesisPhenotypePeripheral blood mononuclear cellAntigenCD28CellCytotoxic T cellReceptorLiposomeChemistryElectroporationIn vitroImmunologyIn vivoT cellChemotherapyCyclophosphamideImmunotherapyCD80B cellLeukemiaMyeloid leukemiaCD19FludarabineGM-CSF ReceptorToxicityChimeric antigen receptorCancer researchMonoclonal antibodyGranulocyte macrophage colony-stimulating factor receptorAntigen-presenting cellMedicineCell cultureBiologyCell biologyPharmacology
8Publications
1H-index
4Citations
Publications 8
Newest
#1Akimasa Tomida (Kyoto Prefectural University of Medicine)H-Index: 1
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 1
Last. Tomoko Iehara (Kyoto Prefectural University of Medicine)H-Index: 21
view all 8 authors...
Disialoganglioside (GD2)-specific chimeric antigen receptor (CAR)-T cells (GD2-CAR-T cells) have been developed and tested in early clinical trials in patients with relapsed/refractory neuroblastoma. However, the effectiveness of immunotherapy using these cells is limited, and requires improvement. A combinatorial therapy with CAR-T cells and molecular targeted drugs could be a promising strategy to enhance the antitumor efficacy of CAR T-cell immunotherapy. Here, we generated GD2-CAR-T cells vi...
Source
#1Kayoko Nakamura (Shinshu University)
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 1
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 9 authors...
Abstract The quality of chimeric antigen receptor (CAR)-T cell products, including the expression of memory and exhaustion markers, has been shown to influence their long-term functionality. The manufacturing process of CAR-T cells should be optimized to prevent early T cell exhaustion during expansion. Activation of T cells by monoclonal antibodies is a critical step for T cell expansion, which may sometimes induce excess stimulation and exhaustion of T cell. Given that piggyBac transposon (PB)...
1 CitationsSource
#1Hasegawa Aiko (Shinshu University)H-Index: 1
#2Shoji Saito (Shinshu University)H-Index: 12
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 16 authors...
Objectives As the prognosis of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains poor, novel treatment strategies are urgently needed. Clinical trials have shown that chimeric antigen receptor (CAR)-T cells for AML are more challenging than those targeting CD19 in B-cell malignancies. We recently developed piggyBac-modified ligand-based CAR-T cells that target CD116/CD131 complexes, also known as the GM-CSF receptor (GMR), for the treatment of juvenile myelomonocytic leukaemia. Thi...
Source
Objectives null Chimeric antigen receptor (CAR)-T cell therapy possesses the potential to cause unexpected on-target toxicities that may be life-threatening. Non-human primates (NHPs) share considerable structural homology and expression profiles of most proteins with humans and are therefore utilised as an animal model for non-clinical safety studies. We have developed a lymphodepleted NHP model by conditioning the animals with immunosuppressive chemotherapy designed to simulate clinical practi...
Source
#1Shoji Saito (Shinshu University)H-Index: 12
#2Hasegawa Aiko (Shinshu University)H-Index: 1
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 13 authors...
Source
#1Shoji Saito (Shinshu University)H-Index: 12
#2Ikumi Nakashima (Shinshu University)
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 7 authors...
Source
#1Hirokazu Morokawa (Shinshu University)H-Index: 2
#2Shigeki Yagyu (Kyoto Prefectural University of Medicine)H-Index: 1
Last. Yozo Nakazawa (Shinshu University)H-Index: 25
view all 9 authors...
Objectives Chimeric antigen receptor (CAR)-T cell therapy redirected to specific antigens on tumor cells is a promising immunotherapy strategy for various cancers. Most target antigens are also expressed on normal tissues at varying levels, and therefore, a considerable challenge in the field is determining safety profiles, including life-threatening off-tumor and off-target toxicities. The granulocyte-macrophage colony-stimulating factor receptor (hGMR) is a promising target for CAR T-cell ther...
2 CitationsSource
#1Hajime HosoiH-Index: 33
#2Tomoko IeharaH-Index: 3
Last. Touru SugimotoH-Index: 3
view all 12 authors...
Abstract Malignant rhabdoid tumor (MRT) is a highly aggressive tumor that occurs in infancy or childhood. The prognosis, especially in infants, is very poor. Here we report the long-term survival of a 5-month-old boy with MRT that arose from the chest wall. After total resection of the tumor, the patient was given 4 cycles of doxorubicin, vincristine, and cyclophosphamide, alternating with ifosfamide and etoposide. After 18 months off therapy, he had a local recurrence at the same site. After a ...
7 CitationsSource